Silo Pharma Receives Nasdaq Notice for Minimum Bid Price Non-Compliance
Silo Pharma receives Nasdaq notice due to minimum bid price non-compliance, initiating a compliance plan to regain listing standards. #SiloPharma #NasdaqCompliance
Executive Summary
Silo Pharma, Inc. (Silo Pharma), a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapies, has received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement. This notice initiates a compliance period during which the company must restore its stock price above the minimum threshold to maintain its Nasdaq listing.
Company Overview
Silo Pharma is engaged in the research and development of novel psychedelic compounds aimed at treating neurological and psychiatric disorders. The company’s pipeline includes several clinical and preclinical stage assets targeting conditions such as depression, anxiety, and PTSD.
Details of Nasdaq Notice
On June 2025, Nasdaq notified Silo Pharma that its common stock had closed below the minimum bid price of $1.00 per share for 30 consecutive business days, triggering a non-compliance status. The company has a compliance period of 180 calendar days to regain compliance by closing at or above $1.00 per share for at least 10 consecutive business days.
Recent Financial Performance (2021-2023)
| Fiscal Year | Revenue (USD Millions) | Net Loss (USD Millions) | Cash and Equivalents (USD Millions) |
|---|---|---|---|
| 2021 | 0.0 | (8.5) | 4.0 |
| 2022 | 0.0 | (10.0) | 3.0 |
| 2023 (Projected) | 0.0 | (12.0) | 2.5 |
Strategic Implications
The Nasdaq notice places pressure on Silo Pharma to improve its stock price through operational progress, investor relations efforts, and potential strategic initiatives. Failure to regain compliance could result in delisting, impacting liquidity and investor confidence.
Risks and Considerations
- Volatility in stock price and market sentiment.
- Clinical and regulatory risks inherent in drug development.
- Potential dilution from future capital raises.
Conclusion
Silo Pharma’s receipt of a Nasdaq notice for minimum bid price non-compliance highlights the challenges faced by early-stage biotech companies. The company’s ability to regain compliance will be critical to maintaining its listing and supporting long-term growth.